Cirrhosis Progression After Variceal Bleeding: Can Early Intervention Slow Progression?
Keywords:
liver cirrhosis, portal hypertension, acute variceal bleeding, rebleeding, decompensation, ACLF, endoscopic band ligation, pre-emptive TIPS, secondary prophylaxisAbstract
Acute variceal bleeding (AVB) remains one of the most dangerous triggers of acute decompensation in liver cirrhosis (LC). A bleeding episode may reduce hepatic reserve through hypovolemia, hypoxia, systemic inflammation and infection, thereby increasing the risk of recurrent bleeding, organ dysfunction and acute-on-chronic liver failure (ACLF). This review evaluates whether early intervention after AVB can influence the subsequent course of cirrhosis. Evidence from contemporary consensus documents, clinical practice guidelines, randomized trials, systematic reviews and individual-patient-data meta-analysis was integrated with observations from our PhD clinical study (2024). Particular attention was paid to early standard management, endoscopic band ligation, secondary prophylaxis and pre-emptive transjugular intrahepatic portosystemic shunt (pTIPS) in high-risk patients. Our five-year clinical observations showed higher rates of hemorrhagic syndrome and functional deterioration among patients with a previous bleeding episode. In the interventional component, a staged endoscopic–endovascular strategy was associated with a reduction in one-year rebleeding from 29.3% to 8.5%. Current evidence suggests that early, risk-adapted management can reduce rebleeding and some decompensation events; however, direct proof that it independently slows the long-term natural progression of cirrhosis remains limited. Standardized prospective endpoints are therefore required.
References
1. R. de Franchis, J. Bosch, G. Garcia-Tsao, et al., “Baveno VII—Renewing consensus in portal hypertension,” J. Hepatol., vol. 76, no. 4, pp. 959–974, 2022, doi: 10.1016/j.jhep.2021.12.022.
2. D. E. Kaplan, C. Ripoll, M. Thiele, et al., “AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis,” Hepatology, vol. 79, no. 5, pp. 1180–1211, 2024, doi: 10.1097/HEP.0000000000000647.
3. European Association for the Study of the Liver, “EASL clinical practice guidelines on acute-on-chronic liver failure,” J. Hepatol., vol. 79, no. 2, pp. 461–491, 2023, doi: 10.1016/j.jhep.2023.04.021.
4. I. M. Gralnek, A. J. Stanley, A. J. Morris, et al., “Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) guideline,” Endoscopy, vol. 54, pp. 1094–1107, 2022, doi: 10.1055/a-1938-7167.
5. J. de la Peña, M. Rivero, E. Sánchez, et al., “Variceal ligation compared with endoscopic sclerotherapy for variceal hemorrhage: Prospective randomized trial,” Gastrointest. Endosc., vol. 49, pp. 142–148, 1999, doi: 10.1016/S0016-5107(99)70036-2.
6. L. Laine and D. Cook, “Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding: A meta-analysis,” Ann. Intern. Med., vol. 123, no. 4, pp. 280–287, 1995, doi: 10.7326/0003-4819-123-4-199508150-00008.
7. Z. Zou, X. Yan, H. Lu, et al., “Comparison of drugs facilitating endoscopy for patients with acute variceal bleeding: A systematic review and network meta-analysis,” Ann. Transl. Med., vol. 7, no. 23, Art. no. 717, 2019, doi: 10.21037/atm.2019.12.26.
8. X. Zhou, D. Tripathi, T. Song, et al., “Terlipressin for the treatment of acute variceal bleeding: A systematic review and meta-analysis of randomized controlled trials,” Medicine (Baltimore), vol. 97, no. 48, Art. no. e13437, 2018, doi: 10.1097/MD.0000000000013437.
9. K. Malandris, P. Paschos, A. Katsoula, et al., “Carvedilol for prevention of variceal bleeding: A systematic review and meta-analysis,” Ann. Gastroenterol., vol. 32, no. 3, pp. 287–297, 2019, doi: 10.20524/aog.2019.0368.
10. X. Qi, Y. Tian, W. Zhang, et al., “Covered TIPS for secondary prophylaxis of variceal bleeding in liver cirrhosis: A systematic review and meta-analysis of randomized controlled trials,” Medicine (Baltimore), vol. 95, no. 50, Art. no. e5680, 2016, doi: 10.1097/MD.0000000000005680.
11. J. C. García-Pagán, K. Caca, C. Bureau, et al., “Early use of TIPS in patients with cirrhosis and variceal bleeding,” N. Engl. J. Med., vol. 362, no. 25, pp. 2370–2379, 2010, doi: 10.1056/NEJMoa0910102.
12. Y. Lv, Z. Yang, L. Liu, et al., “Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: A randomised controlled trial,” Lancet Gastroenterol. Hepatol., vol. 4, no. 8, pp. 587–598, 2019, doi: 10.1016/S2468-1253(19)30142-1.
13. O. Nicoară-Farcău, G. Han, M. Rudler, et al., “Pre-emptive TIPS in high-risk acute variceal bleeding: An updated and revised individual patient data meta-analysis,” Hepatology, vol. 79, no. 3, pp. 624–635, 2024, doi: 10.1097/HEP.0000000000000613.
14. European Association for the Study of the Liver, “EASL clinical practice guidelines on transjugular intrahepatic portosystemic shunt (TIPS),” J. Hepatol., vol. 83, no. 1, pp. 177–210, 2025, doi: 10.1016/j.jhep.2025.01.029.
15. J. C. Garcia-Pagán, M. Di Pascoli, K. Caca, et al., “Use of early-TIPS for high-risk variceal bleeding: Results of a post-RCT surveillance study,” J. Hepatol., vol. 58, no. 1, pp. 45–50, 2013, doi: 10.1016/j.jhep.2012.08.020.
